Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer

Gang Liu, Tao Yin, Hyejin Kim, Chunyong Ding, Zhuo Yu, Hong Wang, Haiying Chen, Ruping Yan, Eric A. Wold, Hao Zou, Xi Liu, Ye Ding, Qiang Shen, Jia Zhou

Research output: Contribution to journalArticle

Abstract

In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 μM and 0.07 μM against triple-negative breast cancer MDA-MB-231 and 3.81 μM and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)589-605
Number of pages17
JournalEuropean journal of medicinal chemistry
Volume178
DOIs
StatePublished - Sep 15 2019

Fingerprint

Triple Negative Breast Neoplasms
Structure-Activity Relationship
Tumors
Bearings (structural)
Cells
Breast Neoplasms
Lead compounds
bcl-2-Associated X Protein
Oncology
Biomarkers
Cytochromes c
Heterografts
Scaffolds
Neoplasms
Nitrogen
Carbon
MCF-7 Cells
Apoptosis
Nude Mice
Atoms

Keywords

  • Bax activator
  • Breast cancer
  • ER-Positive
  • S184
  • SMBA1
  • Therapeutics
  • Triple-negative

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. / Liu, Gang; Yin, Tao; Kim, Hyejin; Ding, Chunyong; Yu, Zhuo; Wang, Hong; Chen, Haiying; Yan, Ruping; Wold, Eric A.; Zou, Hao; Liu, Xi; Ding, Ye; Shen, Qiang; Zhou, Jia.

In: European journal of medicinal chemistry, Vol. 178, 15.09.2019, p. 589-605.

Research output: Contribution to journalArticle

Liu, Gang ; Yin, Tao ; Kim, Hyejin ; Ding, Chunyong ; Yu, Zhuo ; Wang, Hong ; Chen, Haiying ; Yan, Ruping ; Wold, Eric A. ; Zou, Hao ; Liu, Xi ; Ding, Ye ; Shen, Qiang ; Zhou, Jia. / Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. In: European journal of medicinal chemistry. 2019 ; Vol. 178. pp. 589-605.
@article{399c9ea8dbcb447f881184758f6cc87a,
title = "Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer",
abstract = "In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 μM and 0.07 μM against triple-negative breast cancer MDA-MB-231 and 3.81 μM and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer.",
keywords = "Bax activator, Breast cancer, ER-Positive, S184, SMBA1, Therapeutics, Triple-negative",
author = "Gang Liu and Tao Yin and Hyejin Kim and Chunyong Ding and Zhuo Yu and Hong Wang and Haiying Chen and Ruping Yan and Wold, {Eric A.} and Hao Zou and Xi Liu and Ye Ding and Qiang Shen and Jia Zhou",
year = "2019",
month = "9",
day = "15",
doi = "10.1016/j.ejmech.2019.06.004",
language = "English (US)",
volume = "178",
pages = "589--605",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer

AU - Liu, Gang

AU - Yin, Tao

AU - Kim, Hyejin

AU - Ding, Chunyong

AU - Yu, Zhuo

AU - Wang, Hong

AU - Chen, Haiying

AU - Yan, Ruping

AU - Wold, Eric A.

AU - Zou, Hao

AU - Liu, Xi

AU - Ding, Ye

AU - Shen, Qiang

AU - Zhou, Jia

PY - 2019/9/15

Y1 - 2019/9/15

N2 - In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 μM and 0.07 μM against triple-negative breast cancer MDA-MB-231 and 3.81 μM and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer.

AB - In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 μM and 0.07 μM against triple-negative breast cancer MDA-MB-231 and 3.81 μM and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer.

KW - Bax activator

KW - Breast cancer

KW - ER-Positive

KW - S184

KW - SMBA1

KW - Therapeutics

KW - Triple-negative

UR - http://www.scopus.com/inward/record.url?scp=85067297982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067297982&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2019.06.004

DO - 10.1016/j.ejmech.2019.06.004

M3 - Article

VL - 178

SP - 589

EP - 605

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -